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Abstract Background: Postoperative vomiting is a common complication after stra-
bismus surgery in children. The serotonin 5-HT3 receptor antagonists have
proven to be a particularly valuable addition to the armamentarium against
postoperative nausea and vomiting (PONV). Palonosetron is a second-
generation 5-HT3 receptor antagonist that has recently been approved for
prophylaxis against PONV.
Objective: The aim of this study was to evaluate the efficacy of different doses
of palonosetron for the prevention of PONV in children undergoing stra-
bismus surgery.
Patients and Method: A total of 150 children who were classified with an
American Society of Anesthesiologists physical status of I, were aged between
2 and 12 years, and were undergoing strabismus surgery under general an-
esthesia were enrolled in the study. A random numbers table was used to
assign each child to receive palonosetron 0.5, 1.0, or 1.5 mg/kg (n = 50 in each
group). All episodes of PONV at the intervals of 0–2, 2–6, 6–24, and 24–48 hours
were evaluated using a numeric scoring system for PONV. A p-value of <0.05
was considered statistically significant.
Results: The percentage of children with PONV during 0–48 hours after an-
esthesia was 24% with palonosetron 0.5 or 1.0 mg/kg, and 20% with pal-
onosetron 1.5 mg/kg. There was no statistically significant difference between
the study groups with respect to the number of children with PONV scores of
1, 2, or 3 during 0–48 hours after anesthesia. There was no statistically sig-
nificant difference between the study groups with respect to the number of
children with postoperative vomiting during all time periods after anesthesia.
The percentage of children aged >6 years with postoperative nausea during
0–48 hours after anesthesia was 8.6%, 18.2%, and 15.4% with palonosetron
0.5, 1.0, or 1.5 mg/kg, respectively, but there was no statistically significant
difference between the study groups.
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Conclusion: Palonosetron doses of 0.5, 1.0, and 1.5mg/kg are recommended
for further evaluation, as they appear to be the effective doses for the pre-
vention of PONV following strabismus surgery in children.
Introduction
Postoperative nausea and vomiting (PONV)
is experienced by 41–88% of patients following
strabismus surgery when antiemetic prophy-
lactics are not administered.[1-3] Since strabismus
surgery is a notable independent risk factor for
PONV in children, prophylactic administration
of antiemetics is warranted.[4] PONV after stra-
bismus surgery has been studied with all classes of
antiemetics, including butyrophenones, benza-
mides, histamine and muscarinic receptor ant-
agonists, corticosteroids, and serotonin 5-HT3
receptor antagonists.[5,6] Persistent retching or
vomiting can cause tension on suture lines, venous
hypertension, increased bleeding, and can expose
the subject to an increased risk of pulmonary as-
piration of vomitus if airway reflexes are de-
pressed from the residual effects of anesthetic and
analgesic drugs.[7] The area postrema of the brain
stem, where the chemoreceptor trigger zone is
located, is rich in dopamine, opioid, and 5-HT3
receptors.[8-10] These receptors may play an im-
portant role in the transmission of impulses to the
emetic center.[11] The new generation of anti-
emetic agents, called 5-HT3 receptor antagonists
(e.g. ondansetron, granisetron, tropisetron, ramo-
setron, dolasetron), were superior to conventional
antiemetics for the prevention and treatment of
PONV in a review of clinical trials.[12]
Palonosetron, a second-generation 5-HT3 re-
ceptor antagonist, has shown safe and effective
therapeutic properties for the treatment of che-
motherapy-induced nausea and vomiting (CINV)
in children, and has a higher receptor affinity and
a much longer half-life (approximately 40 hours)
than other 5-HT3 receptor antagonists.
[13,14] Pal-
onosetron has been used for the prevention of
acute CINV in patients receiving either moder-
ately or highly emetogenic chemotherapy, and for
the prevention of delayed CINV in patients receiv-
ing moderately emetogenic chemotherapy.[15,16]
In a recent study, compared with the first-gen-
eration 5-HT3 receptor antagonist granisetron,
palonosetron in combination with dexamethasone
demonstrated better control of delayed CINV in
patients receiving highly emetogenic chemothe-
rapy.[17] Recent studies evaluated the efficacy and
safety of palonosetron in preventing PONV.[18,19]
However, to the best of our knowledge, palonose-
tron has never been used after strabismus surgery
in children. This prospective, randomized, double-
blind, single-center study was designed to evaluate
the efficacy of different doses of palonosetron for
the prevention of PONV in children undergoing
strabismus surgery.
Materials and Methods
After obtaining institutional review board ap-
proval and informed parental consent, a pro-
spective, randomized, double-blind, single-center
study was conducted. We enrolled 150 children
from March 2009 to December 2009, who were
classified with an American Society of Anesthesi-
ologists physical status of I, were aged between 2
and 12 years, and were undergoing strabismus
surgery under general anesthesia. Patients who had
a history of motion sickness, prior severe PONV,
known sensitivity to 5-HT3 receptor antagonists,
and who were using any other medication (espe-
cially those having an antiemetic effect, such as
corticosteroids and phenothiazines, in the 24 hours
before surgery) were not included in the study.
Children did not consume milk or solid food for
at least 6 hours before the operation; clear fluids
were allowed until 3 hours before induction of
anesthesia. No pre-anesthetic medications were
administered.
For all patients, the age, sex, bodyweight,
number of eyes and extraocular muscles operated
on, the amount of fluid given intraoperatively,
the agent used for the induction, duration of
30 Bicer et al.
ª 2011 Bicer et al., publisher and licensee Adis Data Information BV. Drugs R D 2011; 11 (1)
anesthesia, recovery time, number of vomiting
episodes, and the number of patients receiving
rescue antiemetic medication were recorded. Heart
rhythm (assessed on ECG), non-invasive blood
pressure, peripheral oxygen saturation, and end-
tidal CO2 were monitored and recorded before
anesthesia induction (baseline), after induction,
before study drug administration, 10 minutes
after study drug administration, and 10 minutes
after extubation.
Anesthesia induction was achieved with thio-
pental sodium 6mg/kg or 8% sevoflurane in 50%
N2O-O2. Tracheal intubation was carried out after
an injection of rocuronium bromide 0.6mg/kg.
Nasogastric decompression was not performed
in any patient. Anesthesia was maintained with
2% sevoflurane in 50% N2O-O2, along with in-
travenous fentanyl 1.0 mg/kg. A random numbers
table was used to assign each child to receive
palonosetron in a dose of 0.5, 1.0, or 1.5 mg/kg be-
fore induction of anesthesia. All study drugs were
prepared in fixed volumes of 5mL by an anes-
thetist who was not otherwise involved in patient
care, in order to maintain the double-blind nature
of the study.
Intraoperative intravenous fluid management
consisted of administration of 5% dextrose with
0.3% saline sufficient to correct for half of
the preoperative fluid deficit in the first hour,
followed by maintenance fluids according to
bodyweight.
At the end of surgery, residual neuromuscular
blockade was antagonized with atropine 0.02mg/kg
and neostigmine 0.05mg/kg, and the trachea was
extubated while the child was awake. The time for
the patients to reach a score of 9 on Aldrete’s
postanesthetic recovery assessment[20] after ex-
tubation was recorded as the recovery time. All
episodes of PONV at the intervals of 0–2, 2–6,
6–24, and 24–48 hours were evaluated using a
numeric scoring system for PONV (0 = no nausea
or vomiting; 1 =nausea but no vomiting; 2 = vom-
iting once in 30 minutes; 3 = two or more episodes
of vomiting in 30 minutes). Postoperatively, all epi-
sodes of retching and vomiting were recorded
by nursing staff who did not know which treat-
ment each patient had received.We did not assess
nausea in very young children (<6 years). Any
child having a score of 3 was considered to have
severe vomiting and was treated with intravenous
metoclopramide 150 mg/kg as a rescue antiemetic.
Postoperatively, analgesia was provided if older
children reported pain or if younger children
cried. Oral ibuprofen 10mg/kg was given as the
analgesic of first choice, and, for pain in children
who had PONV in the immediate postoperative
period in the postanesthesia care unit, meperidine
0.5mg/kg was administered intravenously as the
analgesic of second choice by the anesthesiologist
who provided intraoperative care. Potential ad-
verse events due to the study drug, such as head-
ache and constipation, were also recorded after
the operation by either questioning the children,
interviewing the parents of the patients, or ob-
servation by the nurses.
The primary objective of the study was to de-
termine the dose-response relationship of single
intravenous doses of palonosetron (0.5, 1.0, or
1.5 mg/kg) for the prevention of PONV in children
undergoing strabismus surgery. The primary
outcome variable was the proportion of patients
with PONV during the 48-hour period following
surgery. Secondary measures were assessed for
48 hours after strabismus surgery and included
the number of children with PONV scores of 1, 2,
and 3, the number of children who needed rescue
antiemetic, and assessment of potential adverse
events.
Statistical Analysis
The primary efficacy hypotheses of the study
were that (i) there is no difference in the pro-
portion of patients with no nausea or emetic ep-
isodes between the groups receiving palonosetron
0.5, 1.0, or 1.5 mg/kg; and (ii) each dose of pal-
onosetron is able to induce a decrease of at least
50% in the incidence of PONV in the study pop-
ulation compared with the control population
(i.e. patients receiving no antiemetic prophylaxis).
Tosun et al.[21] have previously reported the in-
cidence of PONV in children undergoing stra-
bismus surgery as 60% in our clinic. With respect
to that study, using a= 0.05 and b = 0.2 for each
comparison, the sample size in the current study
was estimated at 48 evaluable patients per group,
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rounded up to 50 patients per group (Sample-Size
Software, NCSS-PASS, Kaysville, UT, USA).
Statistical analyses were performed using SPSS
(version 15.0, SPSS, Inc., Chicago, IL, USA)
software.Whether the data had normal distribution
or not was assessed by the Kolmogorov-Smirnov
test. A one-way ANOVA test was used for the
comparison of the parametric data with normal
distribution between the groups. Statistical sig-
nificance was determined by the Tukey Test,
which is a post hocmultiple-comparison test. The
repeated measures ANOVA test was performed
for in-group comparisons. For the evaluation of
parametric data without normal distribution, the
Kruskal-Wallis test was used. PONV, induction
agent, rescue antiemetic, operated eye and extra-
ocular muscles, adverse effects, and sex were
evaluated by the Chi-squared test. A p-value of
<0.05 was accepted as statistically significant.
Results
The demographic data and clinical data, such
as patient age, sex, bodyweight, intraoperative
fluid requirement, duration of surgery, recovery
time, and postoperative analgesic drug require-
ments were similar among all groups (table I). A
total of 20, 20, and 15 patients had an inhalation
induction of anesthesia with 8% sevoflurane in
50% N2O-O2, and 30, 30, and 35 patients had an
intravenous induction of anesthesia with thiopental
sodium 6mg/kg in the palonosetron 0.5, 1.0, and
1.5 mg/kg groups, respectively.
The number of children who needed metoclo-
pramide as a rescue antiemetic was five, two, and
one in the palonosetron 0.5, 1.0, and 1.5 mg/kg
groups, respectively, but the difference was not
statistically significant (table I). None of the
children in all three study groups had vomiting
after the intravenous metoclopramide 150 mg/kg
rescue injection.
The percentage of children with PONV dur-
ing 0–48 hours after anesthesia was 24% with
palonosetron 0.5mg/kg (12 patients) and 1.0mg/kg
(12 patients), and 20% (10 patients) with pal-
onosetron 1.5mg/kg.
There was no statistically significant difference
between the study groups with respect to the
number of children with PONV scores of 1, 2, or
3 during 0–48 hours after anesthesia (table II).
During all time periods after anesthesia, there
was no statistically significant difference between
the study groups with respect to the number of
children with vomiting (table II).
The percentage of children aged >6 years with
nausea during 0–48 hours after anesthesia was
8.6% (three patients), 18.2% (six patients), and
15.4% (six patients) with palonosetron 0.5, 1.0, or
1.5 mg/kg, respectively, but there was no statisti-
cally significant difference between the study
groups (table II).
There was no statistically significant difference
between the study groups with respect to the type
Table I. Demographic and clinical data







Age (y) [mean –SD] 7.94 –3.1 7.68 – 3.3 8.36 –3.0 0.566
Bodyweight (kg) [mean –SD] 28.7 –11.2 27.9 – 12.4 29.3 –11.8 0.835
Sex (M/F) [n (%)] 24 (48)/26 (52) 25 (50)/25 (50) 28 (56)/22 (44) 0.707
Induction agent (sevoflurane/thiopental) [n (%)] 20 (40)/30 (60) 20 (40)/30 (60) 15 (30)/35 (70) 0.488
Intraoperative fluid (mL) [median (range)] 200 (100–500) 200 (50–500) 200 (70–600) 0.888
Duration of surgery (min) [mean –SD] 47.7 –16.4 45.2 – 16.3 47.9 –16.8 0.663
Recovery time (min) [mean –SD] 8.9 – 4.1 10.0 – 4.7 9.7 –4.7 0.415
Rescue antiemetic in hospital [n (%)] 5 (10) 2 (4) 1 (2) 0.180
Postoperative requirements of IV meperidine [n (%)] 7 (14) 5 (10) 3 (6) 0.411
Postoperative requirements of oral ibuprofen [n (%)] 13 (26) 15 (30) 16 (32) 0.798
IV = intravenous.
32 Bicer et al.
ª 2011 Bicer et al., publisher and licensee Adis Data Information BV. Drugs R D 2011; 11 (1)
of surgery conducted (e.g. recession, advancement
[resection], myotomy,muscle resection or recession
dosages [mm]), or number of muscles repaired
(table III).
In this study, all doses of palonosetron were
well tolerated. Clinically serious adverse events
(e.g. headache, constipation) caused by the study
drug were not observed in any of the study
groups. There was no statistically significant dif-
ference between study groups with respect to
mean arterial blood pressures and heart rates re-
corded perioperatively.
Discussion
The reported incidence of PONV after pedia-
tric strabismus surgery was 60%[21] and 85%[22] in
previously published studies when no prophy-
lactic antiemetic is given. The primary outcome
of the current study was to determine the dose-
response relationship of single intravenous doses
of palonosetron for the prevention of PONV in
children undergoing strabismus surgery. The
study demonstrated that 0.5 mg/kg of palonose-
tron was as effective as higher doses in reducing
the incidence of PONV.
In the literature, there are only a few clini-
cal studies for the use of palonosetron in the
prevention of PONV in specific surgical sit-
uations.[18,23] These specific situations were lap-
aroscopic abdominal or gynecologic surgery, and
major gynecologic surgery. White and Scuderi[23]
used palonosetron in a range of 0.1–30 mg/kg
doses in abdominal or vaginal hysterectomy pro-
cedures and reported that intravenous palonose-
tron 1 and 30mg/kg significantly reduced PONV
compared with placebo treatment. In another
study comparing the efficacy and safety of three
different doses of palonosetron (0.025, 0.050,
and 0.075mg) with placebo for the prevention
of PONV for up to 72 hours in women under-
going general anesthesia for elective gynecologic
or breast surgery, the authors reported that a
single 0.075mg dose of intravenous palonosetron
(i) significantly increased the rates of no emetic
episodes and no rescue medication from 0 to
24 hours (p = 0.004); (ii) decreased nausea severity
(p = 0.042); and (iii) significantly decreased inter-
ference in patient postoperative recovery due
to PONV (p = 0.004).[18] Sepu´lveda-Vildo´sola
et al.[14] used palonosetron 3–19 mg/kg to prevent
CINV in children, and concluded that palonose-
tron is a safe and effective antiemetic drug in this
patient population. However, no studies have
evaluated the dose-response and clinical useful-
ness of prophylactic palonosetron in children
undergoing strabismus repair (a procedure that
carries the high risk of PONV) alone.
In the present study, we compare three differ-
ent doses of palonosetron (0.5, 1.0, and 1.5 mg/kg)
to find the lowest dose of palonosetron that is
effective in preventing PONV in children under-
going strabismus surgery. Dose selection was
based on findings of an earlier study that eval-
uated intravenous doses of palonosetron ranging
from 0.1 to 30 mg/kg.[23] Our study is the first to
Table II. Incidence and severity of postoperative nausea and vomit-
ing (PONV)a







PONV scoreb (0–48 h)
0 38 (76) 38 (76) 40 (80) 0.859
1 2 (4) 5 (10) 4 (8) 0.503
2 5 (10) 5 (10) 5 (10) 1.000
3 5 (10) 2 (4) 1 (2) 0.180
Vomiting during postoperative time interval (h)
0–2 10 (20) 7 (14) 7 (14) 0.640
2–6 1 (2) 0 (0) 1 (2) 0.602
6–24 0 (0) 0 (0) 0 (0)
24–48 0 (0) 0 (0) 0 (0)
0–48 11 (22) 7 (14) 8 (16) 0.272
Nauseac during postoperative time interval (h)
0–2 1 (2.9) 5 (15.2) 6 (15.4) 0.161
2–6 2 (5.7) 1 (3) 0 (0) 0.330
6–24 0 (0) 0 (0) 0 (0)
24–48 0 (0) 0 (0) 0 (0)
0–48 3 (8.6) 6 (18.2) 6 (15.4) 0.497
a Values are expressed as n (%).
b 0 =no nausea or vomiting; 1 =nausea but no vomiting; 2= vom-
iting once in 30 minutes; 3 = two or more episodes of vomiting
in 30 minutes.
c Nausea was only assessed in patients aged >6 years: palonose-
tron 0.5 mg/kg (n =35), 1.0 mg/kg (n =33), and 1.5 mg/kg (n =39).
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make a recommendation of palonosetron dose
based on comparison among three different
bodyweight-adjusted doses in children under-
going strabismus surgery. This is especially im-
portant in pediatric patients, because the use of
predetermined doses irrespective of bodyweight
may lead to administration of either an inadequate
or an excessive dose of palonosetron resulting in
lack of efficacy or occurrence of adverse effects,
respectively.
The incidence of PONV in our palonosetron
groups was similar to that reported in previous
5-HT3 inhibitor studies.
[21,24,25] The elimination
half-life of palonosetron (reported to be approx-
imately 40 hours[13]) is longer than that of other
5-HT3 receptor antagonists (e.g. granisetron
5–8 hours, ondansetron 3–5 hours, ramosetron
4.3–9 hours, tropisetron 8 hours). This long half-
life permits one dose of palonosetron to be
enough for the prevention of PONV after stra-
bismus surgery.
In this study, the groups were comparable with
respect to patient characteristics, hemodynamic
variables, surgical procedure (recession, resection,
and myotomy), and anesthetics administered.
Therefore, any difference in the incidence and se-
verity of PONV among the groups in this study
could be attributed to the three different doses of
the study antiemetic that was administered.
Due to the increasing cost of care for PONV,
cost effectiveness continues to be a major concern
when choosing therapeutic agents. Proper dos-
age, the emetic potential of the surgical procedure
and anesthetic agents, and patient history of res-
ponse to 5-HT3 receptor antagonists are im-
portant factors to consider when choosing agents
within the class. However, there is a large cost dif-
ference between palonosetron and other 5-HT3
receptor antagonists. With respect to palonose-
tron, it is difficult to decide how much added cost
the added benefit is worth.
One possible limitation of this study was that
we could not compare the effect of palonosetron
with placebo. More than half of all patients un-
dergoing pediatric strabismus surgery experience
PONV and, therefore, it would be unethical to
use a placebo group in this pediatric population.
Another possible limitation of this study may be
the short duration of the study period (48 hours).
Due to both the long half-life and long-lasting
functional effects of palonosetron compared with
other 5-HT3 receptor antagonists, PONV may be
assessed for 72 hours; however, in our study,
patients were discharged from the hospital after
Table III. The number of operated eyes and extraocular muscles, and type of surgery







Surgery of one eye/both eyes (n) 28/22 26/24 26/24 0.898
Type of surgery
advancement [resection] (n) 0 1 1 0.602
recession (n) 11 15 13 0.660
advancement and recession (n) 19 12 17 0.303
myotomy (n) 20 22 19 0.824
Surgical dosages
resection (mm) [mean –SD] 6.7 –0.8 6.2 –1.4 6.5 –1.6 0.525
recession (mm) [mean –SD] 6.6 –2.7 6.2 –1.3 6.1 –1.7 0.709
Number of operated muscles (n/PONV)
1 9/3 15/4 10/1 >0.05
2 38/7 31/6 36/9 >0.05
3 2/2 1/1 2/0 >0.05
4 1/0 3/1 2/0 >0.05
PONV = postoperative nausea and vomiting.
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48 hours, and parents were not contacted the day
after hospital discharge for further assessment of
PONV and potential adverse effects.
The low population size for a dose-response
trial is also a limitation of this study, with per-
haps too few patients in each treatment group for
a robust statistical evaluation of the treatment
effect on all endpoints and at all time intervals to
be conducted. An example of this limitation was
the low rate of rescue medication use in the pal-
onosetron 1.5 mg/kg (one patient) group com-
pared with that observed in the 0.5 mg/kg (five
patients) and 1.0 mg/kg (two patients) groups
during the 0- to 48-hour interval after surgery.
Although there was a reduction in the incidence
of rescue medication use, it did not prove to
be statistically significant (p = 0.180). Due to the
overall low rate of rescue medication use, it is
difficult to make conclusions about the efficacy
of the drug in this respect.
Based on the results of this study, fixed pal-
onosetron doses of 0.5, 1.0, and 1.5 mg/kg are rec-
ommended for further evaluation, as they appear
to be the effective doses for the prevention of PONV
following strabismus surgery in children.
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